AK137 (Bispecific Antibody Targeting CD73 and LAG-3) in Patients With Advanced Malignant Tumors

Phase 1 Not yet recruiting 87 enrolled Akeso

NaSingle-groupOpen-labelTreatment

Summary

A Phase I open label, dose-escalation and expansion study to evaluate the safety, tolerability, pharmacokinetics and antitumor activity of AK137 in patients with advanced malignant tumors.

Timeline

Start: 2024-12
Primary completion: 2027-05
Completion: 2027-08

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	AK137	Unknown	—	Intravenous

AK137 (Bispecific Antibody Targeting CD73 and LAG-3) in Patients With Advanced Malignant Tumors

Summary

Timeline

Drugs

Indications